Answers are grounded in this paper and cite their sources.
SUMMARY Transfusion of red blood cells (RBC) continues to be an important therapy for treatment of anemia in intensive care settings. The critically ill are a heterogeneous population affected by a variety of pathophysiological processes and are, therefore, predisposed to the – adverse outcomes of anemia. As such, the risks imposed on this population when transfusion therapy is prescribed are of great interest. Over the past decade there has been a shift in transfusion practice with guidelines being developed that promote more conservative and safer use of blood. The Transfusion Requirements in Critical Care (TRICC) trial clearly established the safety of a restrictive transfusion strategy, thereby suggesting that physicians could easily minimize exposure to allogeneic RBCs by lowering their transfusion threshold. Further research will add to the generalizability of this study as well as explore the possible mechanism to explain why red cell transfusions did not improve outcomes in the critically ill.
No takes yet. Share an insight, caveat, or question.
Paul C. Hébert (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: